Brief: AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss Up To About 10% Over 3-Month Period
30/09/2026 10:45
BRIEF-AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss Up To About 10% Over 3-Month Period Sept 30 (Reuters) - AbbVie Inc. ABBV.N:
ABBVIE: IN PHASE 1 ABBV-295 STUDY, ALL DOSING REGIMENS RESULTED IN LS MEAN WEIGHT LOSS UP TO ABOUT 10% OVER 3-MONTH TREATMENT PERIOD
ABBVIE: 82.2% OF ALL ABBV-295 TREATED PARTICIPANTS REPORTED MILD ADVERSE EVENTS AS HIGHEST REPORTED AE SEVERITY
Further company coverage: ABBV.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96